Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Antibody responses to Plasmodium vivax Duffy binding and Erythrocyte binding proteins predict risk of infection and are associated with protection from clinical Malaria.

He WQ, Shakri AR, Bhardwaj R, França CT, Stanisic DI, Healer J, Kiniboro B, Robinson LJ, Guillotte-Blisnick M, Huon C, Siba P, Cowman A, King CL, Tham WH, Chitnis CE, Mueller I.

PLoS Negl Trop Dis. 2019 Feb 15;13(2):e0006987. doi: 10.1371/journal.pntd.0006987. eCollection 2019 Feb.

2.

Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial.

Singh K, Mukherjee P, Shakri AR, Singh A, Pandey G, Bakshi M, Uppal G, Jena R, Rawat A, Kumar P, Bhardwaj R, Yazdani SS, Hans D, Mehta S, Srinivasan A, Anil K, Madhusudhan RL, Patel J, Singh A, Rao R, Gangireddy S, Patil R, Kaviraj S, Singh S, Carter D, Reed S, Kaslow DC, Birkett A, Chauhan VS, Chitnis CE.

NPJ Vaccines. 2018 Sep 28;3:48. doi: 10.1038/s41541-018-0083-3. eCollection 2018.

3.

Targeting a Reticulocyte Binding Protein and Duffy Binding Protein to Inhibit Reticulocyte Invasion by Plasmodium vivax.

Gupta S, Singh S, Popovici J, Roesch C, Shakri AR, Guillotte-Blisnick M, Huon C, Menard D, Chitnis CE.

Sci Rep. 2018 Jul 12;8(1):10511. doi: 10.1038/s41598-018-28757-4.

4.

Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.

Payne RO, Silk SE, Elias SC, Milne KH, Rawlinson TA, Llewellyn D, Shakri AR, Jin J, Labbé GM, Edwards NJ, Poulton ID, Roberts R, Farid R, Jørgensen T, Alanine DG, de Cassan SC, Higgins MK, Otto TD, McCarthy JS, de Jongh WA, Nicosia A, Moyle S, Hill AV, Berrie E, Chitnis CE, Lawrie AM, Draper SJ.

JCI Insight. 2017 Jun 15;2(12). pii: 93683. doi: 10.1172/jci.insight.93683. eCollection 2017 Jun 15.

5.

Production of recombinant PvDBPII, receptor binding domain of Plasmodium vivax Duffy binding protein, and evaluation of immunogenicity to identify an adjuvant formulation for vaccine development.

Bhardwaj R, Shakri AR, Hans D, Gupta P, Fernandez-Becerra C, Del Portillo HA, Pandey G, Chitnis CE.

Protein Expr Purif. 2017 Aug;136:52-57. doi: 10.1016/j.pep.2015.06.011. Epub 2015 Nov 11.

PMID:
26578115
6.

Development of vaccines for Plasmodium vivax malaria.

Mueller I, Shakri AR, Chitnis CE.

Vaccine. 2015 Dec 22;33(52):7489-95. doi: 10.1016/j.vaccine.2015.09.060. Epub 2015 Oct 1. Review.

7.

Correction: Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.

Chitnis CE, Mukherjee P, Mehta S, Yazdani SS, Dhawan S, Shakri AR, Bhardwaj R, Gupta PK, Hans D, Mazumdar S, Singh B, Kumar S, Pandey G, Parulekar V, Imbault N, Shivyogi P, Godbole G, Mohan K, Leroy O, Singh K, Chauhan VS.

PLoS One. 2015 Sep 2;10(9):e0137816. doi: 10.1371/journal.pone.0137816. eCollection 2015.

8.

Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax.

de Cassan SC, Shakri AR, Llewellyn D, Elias SC, Cho JS, Goodman AL, Jin J, Douglas AD, Suwanarusk R, Nosten FH, Rénia L, Russell B, Chitnis CE, Draper SJ.

Front Immunol. 2015 Jul 8;6:348. doi: 10.3389/fimmu.2015.00348. eCollection 2015.

9.

Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.

Chitnis CE, Mukherjee P, Mehta S, Yazdani SS, Dhawan S, Shakri AR, Bhardwaj R, Gupta PK, Hans D, Mazumdar S, Singh B, Kumar S, Pandey G, Parulekar V, Imbault N, Shivyogi P, Godbole G, Mohan K, Leroy O, Singh K, Chauhan VS.

PLoS One. 2015 Apr 30;10(4):e0117820. doi: 10.1371/journal.pone.0117820. eCollection 2015. Erratum in: PLoS One. 2015;10(9):e0137816. Bharadwaj, Rukmini [corrected to Bhardwaj, Rukmini].

10.

Development of quantitative receptor-ligand binding assay for use as a tool to estimate immune responses against Plasmodium vivax Duffy binding protein Region II.

Shakri AR, Rizvi MM, Chitnis CE.

J Immunoassay Immunochem. 2012;33(4):403-13. doi: 10.1080/15321819.2012.659781.

PMID:
22963489
11.

Targeting TLRs expands the antibody repertoire in response to a malaria vaccine.

Wiley SR, Raman VS, Desbien A, Bailor HR, Bhardwaj R, Shakri AR, Reed SG, Chitnis CE, Carter D.

Sci Transl Med. 2011 Jul 27;3(93):93ra69. doi: 10.1126/scitranslmed.3002135.

12.

Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.

Moreno A, Caro-Aguilar I, Yazdani SS, Shakri AR, Lapp S, Strobert E, McClure H, Chitnis CE, Galinski MR.

Vaccine. 2008 Aug 12;26(34):4338-44. doi: 10.1016/j.vaccine.2008.06.010. Epub 2008 Jun 23.

13.

Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection.

King CL, Michon P, Shakri AR, Marcotty A, Stanisic D, Zimmerman PA, Cole-Tobian JL, Mueller I, Chitnis CE.

Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8363-8. doi: 10.1073/pnas.0800371105. Epub 2008 Jun 3.

14.

Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.

Devi YS, Mukherjee P, Yazdani SS, Shakri AR, Mazumdar S, Pandey S, Chitnis CE, Chauhan VS.

Vaccine. 2007 Jul 9;25(28):5166-74. Epub 2007 May 21.

PMID:
17544179
15.

Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.

Pattnaik P, Shakri AR, Singh S, Goel S, Mukherjee P, Chitnis CE.

Vaccine. 2007 Jan 15;25(5):806-13. Epub 2006 Sep 27.

PMID:
17045706
16.

Improvement in yield and purity of a recombinant malaria vaccine candidate based on the receptor-binding domain of Plasmodium vivax Duffy binding protein by codon optimization.

Yazdani SS, Shakri AR, Pattnaik P, Rizvi MM, Chitnis CE.

Biotechnol Lett. 2006 Jul;28(14):1109-14. Epub 2006 Jun 23.

PMID:
16794771
17.

Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys.

Arévalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, Dominik R, Herrera S.

Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):25-31.

PMID:
16291763
18.

Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion.

Hans D, Pattnaik P, Bhattacharyya A, Shakri AR, Yazdani SS, Sharma M, Choe H, Farzan M, Chitnis CE.

Mol Microbiol. 2005 Mar;55(5):1423-34.

19.

A high cell density fermentation strategy to produce recombinant malarial antigen in E. coli.

Yazdani SS, Shakri AR, Chitnis CE.

Biotechnol Lett. 2004 Dec;26(24):1891-5.

PMID:
15672234
20.

Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein.

Yazdani SS, Shakri AR, Mukherjee P, Baniwal SK, Chitnis CE.

Vaccine. 2004 Sep 9;22(27-28):3727-37.

PMID:
15315853

Supplemental Content

Loading ...
Support Center